#### VERIFICATION OF TRANSLATION

## I, Naoto Sato

of 6th Fl., Kantetsu Tsukuba-Science-City Bldg. 1-1-1, Oroshi-machi, Tsuchiura, Ibaraki, JAPAN

declare as follows:

- 1. That I am well acquainted with both the English and Japanese languages, and
- 2. That the attached document is a true and correct translation of a certified copy of the following application, which was made by me to the best of my knowledge and belief of.

Japanese Patent Application No. 2002-313076
Entitled: "METHOD TO ESTIMATE THE INHERITED RESISTANCE AND SUSCEPTIBILITY TO RNA VIRUS DISEASE IN PIGS"

Filed on October 28, 2002

ber 26.2008

Date

Naoto Sato

[Name of Document] APPLICATION FOR PATENT [Identification Number] MOA-A0214 [Filing Date] October 28, 2002 [Addressee] Esq. Commissioner of the Patent Office [Inventor] [Address] 26-405-501, Matsushiro 4chome, Tsukuba-shi, Ibaraki [Name] MITSUHASHI, Tadayoshi [Applicant] [Identification Number] 501167644 National Institute of Agrobiological Sciences [Name or Appellation] [Attorney] 100102978 [Identification Number] [Patent Attorney] [Name or Appellation] Hatsushi Shimizu [Nominated Attorney] [Identification Number] 100108774 [Patent Attorney] [Name or Appellation] Kazunori Hashimoto [Payment] [Registration Number] 041092 [Amount] 21000 yen [List of Attached Documents] Name of Document Specification 1 [Name of Document] Drawings 1 [Name of Document] Abstract 1 [Proof] Necessary

## [Document Name] Specification

[Title of the Invention] Method to estimate the inherited resistance and susceptibility to RNA virus disease in pigs

5

10

15

20

### [Claims]

[Claim 1] A method for determining a pig's resistance to an influenza virus, wherein the method comprises the step of detecting an 11-bp deletion in a swine Mx1 gene exon, wherein the deletion is from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1.

[Claim 2] The method according to claim 1, comprising the steps of:

- (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1; and
- (c) determining the nucleotide sequence of the amplified DNA.

[Claim 3] The method according to claim 1, comprising the steps of:

- (a) preparing a DNA sample from a subject pig;
- (b) digesting the prepared DNA with a restriction enzyme;
- (c) separating DNA fragments based on their size; and
- (d) comparing the sizes of detected DNA fragments with that of a control.

[Claim 4] The method according to claim 1, comprising the steps of:

- (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
- (c) digesting the amplified DNA with a restriction enzyme;
- 25 (d) separating DNA fragments based on their size; and
  - (e) comparing the sizes of detected DNA fragments with that of a control.

[Claim 5] The method according to claim 1, comprising the steps of:

- (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence
- from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
  - (c) dissociating the amplified DNA into single strands;
  - (d) separating the dissociated single-stranded DNAs on a non-denaturing gel; and
  - (e) comparing the gel mobility of the fractionated single-stranded DNAs with that of a control.

[Claim 6] The method according to claim 1, comprising the steps of:

- 35 (a) preparing a DNA sample from a subject pig;
  - (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence

from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;

- (c) determining the molecular weight of the DNA amplified in step (b) by mass spectrometry; and
- (d) comparing the molecular weight determined in step (c) with that of a control.

[Claim 7] The method according to claim 1, comprising the steps of:

(a) preparing a DNA sample from a subject pig;

5

20

25

30

- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
- (c) preparing a substrate with an immobilized nucleotide probe;
- 10 (d) contacting the DNA prepared in step (b) with the substrate prepared in step (c);
  - (e) determining the intensity of hybridization between the DNA and the nucleotide probe immobilized on the substrate; and
  - (f) comparing the intensity determined in step (e) with that of a control.

[Claim 8] The method according to claim 1, comprising the steps of:

- 15 (a) preparing a protein sample from a subject pig; and
  - (b) determining the amount of a mutant swine Mx1 protein in the protein sample, wherein said mutant swine Mx1 protein is encoded by a nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp nucleotide sequence from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted.

[Claim 9] An oligonucleotide that is a PCR primer for the method for determining of claim 1, wherein the oligonucleotide is used to amplify a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1.

[Claim 10] An oligonucleotide comprising at least 15 nucleotides, and hybridizing to a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a DNA region that is a swine Mx1 gene exon and comprises a nucleotide sequence in which the nucleotide sequence from positions 1964 to 1974 has been deleted.

[Claim 11] An antibody recognizing a mutant swine Mx1 protein encoded by the nucleotide sequence of a swine Mx1 gene exon in which the nucleotide sequence from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted.

[Claim 12] A test reagent for determining a pig's resistance to an influenza virus, wherein the reagent comprises the oligonucleotide according to claim 9 or 10, or the antibody according to claim 11.

[Detailed Description of the Invention]

[Technical Field of Industrial Application]

[0001]

The present invention relates to methods for determining genetic resistance of pigs to diseases caused by RNA viruses.

[Prior Art]

5

10

15

20

25

30

35

[0002]

Mouse studies have shown that the Mx gene encodes a protein that suppresses propagation (inhibits RNA synthesis) of RNA viruses belonging to the orthomyxovirus family (single-stranded linear RNA viruses), such as influenza viruses.

[0003]

One of the two swine Mx genes is the Mx1 gene, consisting of 14 exons. Some pigs of the Meishan breed have a 3-bp (Ser) deletion in exon 13. On the other hand, some animals of pig breeds that are domesticated in the West and widely used around the world, such as Landrace and Duroc, have an 11-base deletion in the last exon (see Non-Patent Document 1).

[0004]

The present inventors have previously reported the presence of Mx1 deletion genotypes and their frequencies (see Non-Patent Document 1) through collaboration with the STAFF Institute. Among these deletion genotypes, an 11-base deletion type without virus-suppressing ability was found to exist at a high frequency in Landrace, which is the most commonly used swine breed in the world. Landrace (Fig. 1 photograph) has been widely used to raise three-way crossbreds for fattening/production.

[0005]

On the other hand, the 11-base deletion has not been found in wild or half-wild species such as the Japanese wild boar and Meishan pig.

[0006]

The homozygous C was conceivably against the survival of pigs, since, for example, the percentage of homozygous C present in the Landrace breed was lower than that of the heterozygous C, and in other breeds only heterozygous but no homozygous pigs exist. No homozygous (C/C) pigs were found in the survey of about 40 pigs of white Western breeds, including Landrace, in the old National Institute of Animal Industry in the year 2000.

[0007]

The largest worldwide influenza epidemic in history, called the Spanish influenza epidemic, occurred between 1917-1918 and led to 20-40 million deaths. In Japan, more than 300,000 people died. The Spanish influenza epidemic, which started in the Northwest region of

the United States, killed approximately 600,000 people in the United States alone. At that time, a cold outbreak in the pig population was also reported. There was also a report on the phylogenetic analysis of an RNA virus obtained from formalin-preserved, paraffin-embedded lung tissue samples taken from soldiers who died during the epidemic. According to the report, the influenza virus is very close to those infectious for pigs.

[8000]

5

10

15

20

25

30

Pig farming is still popular in the Northwest region of the United States including the Iowa State. There is no detailed information on pig farming at the time of the outbreak, but if the Landrace breed or its crossbreeds were being raised on a large scale, pig populations having a high percentage of pigs susceptible to influenza viruses may have been acting as a breeding ground for the new virus and resulting in the pandemic.

[0009]

Farm animals are bred at high densities within limited areas of fixed locations. High-density breeding can mean major damages to production as disease spreads easily through the herd after an initial outbreak. As is evident from examples of influenza transmission from pigs to humans, high-density livestock herds sometimes can act as a breeding ground that transmits diseases to populations across species. To prevent such risks, preventive vaccination is used nowadays, and antibiotics-containing feed is given to animals even if they are in a healthy state. In spite of such preventive measures, great losses in pig production can occur, as exemplified by the outbreak of a new type influenza virus H3N2 in the United States between 1998-2000. Routine administration of antibiotics may result in antibiotics remaining in meat products, and therefore trigger food safety concerns among consumers. However, the preventive measures are necessary for reducing livestock losses from diseases. Genetic information governing potential disease resistance in livestock is required to maintain food safety while retaining or improving the current rate of disease suppression. Nevertheless, such information is still yet to be found.

[0010]

In addition, so far there is no effective method available for determining genetic resistance of pigs to diseases caused by RNA viruses.

[0011]

[Non-Patent Document 1]

Morozumi T. et al., "Three types of olymorphisms in exon 14 in porcine Mx1 gene", Biochemical Genetics., (2001) Vol. 39, p. 251-260

35 [Problems to be Solved by the Invention]

[0012]

The present invention was achieved under the above circumstances. An objective of the invention is to provide methods for determining genetic resistance of pigs to diseases caused by RNA viruses.

## 5 [Means for Solving the Problems]

[0013]

10

15

20

25

30

35

Some particular livestock and livestock breedsmay have the genetically-inherited disease resistance characteristic of "low productivity, but high resistance to certain diseases". If such a hereditary characteristic of disease resistance can be introduced into breeds with high productivity, breeds of high productivity and high disease resistance can be created. This would enable the reduction of the amounts of antibiotics required. It has been difficult to identify the genetic basis governing such hereditary characteristics at the molecular level. However, the advancement of molecular genetics has accelerated the elucidation of genetic bases of various hereditary characteristics in human and mouse. If the resistance to a particular disease can be related to some of the genetic information in farm animals, disease resistant livestock can be selected and bred based on such genetic information.

[0014]

In a previous study, the inventors revealed that among domesticated pigs, some have an 11-base deletion in the gene encoding the Mx1 protein, which is responsible for the suppression of myxovirus propagation (already disclosed in a published document). Then, the inventors noticed a lower ratio of animals with homozygous deletion genotype compared to those with heterozygous deletion genotype. The inventors understood from pig farming experiences that pigs have poor resistance to respiratory diseases and that this has a huge impact on piglet production. The present inventors then investigated the effects of the 11-bp deletion in the Mx1 gene on the ability to suppress propagation of influenza viruses (members of the myxovirus family), and revealed that the 11-bp deletants completely lost the ability to suppress virus propagation, and thereby completed the present invention.

[0015]

More specifically, in Mx1 genes carrying the 11-base deletion in the last exon, the 11-base deletion causes frame shift of codons (single units of triplicate nucleotides), which relocates the stop codon to a much further position downstream and thus dramatically alters the downstream amino acid sequence. The resultant mutant Mx1 protein has a different molecular weight and structure compared to the normal (wild-type) protein, and has probably lost its ability to suppress virus propagation because of that.

[0016]

Next, the present inventors introduced a normal (wild-type) Mx1 gene, a mutant Mx1

gene containing a 3-base (3-bp) deletion in exon 13, a mutant Mx1 gene containing the 11-base (11-bp) deletion in the last exon, or an empty vector into murine 3T3 cells which have no Mx1 activity, and performed influenza A virus infection experiments.

[0017]

5

10

15

20

25

30

The results showed that the 11-bp deletant completely lost its ability to suppress virus propagation (arrow on the far left of Fig. 2), and had a virus propagation comparable to that of the empty vector, which was 10-100 times higher than the wild type. In addition, the 3-bp deletant had a virus propagation curve comparable to that of the wild type and the deletion did not affect the virus suppression ability. The deletant thus maintained the ability to suppress virus propagation (arrow on the far right of Fig. 2). Similar results were obtained in a separate experiment of virus infection at a multiplicity of infection that is one order of magnitude smaller (MOI = 1).

[0018]

In particular, among the domestic pigs used around the world, there are some that carry an Mx1 gene that lacks the ability to suppress viral propagation. According to the experimental results of the present invention, such pigs are expected to have a serious defect in their defense ability during the early phase defense against an RNA virus invasion.

[0019]

Specifically, the above-described genotype of the swine Mx1 gene can be used to determine the genetic resistance of pigs to diseases caused by RNA viruses. In addition, it is important to eliminate the 11-base Mx1 deletants not only for the health of livestock, but also for eliminating threats that arise from emergence of new influenza viruses that are infectious to humans.

[0020]

- The present invention relates to methods for determining genetic resistance of pigs to diseases caused by RNA viruses. More specifically, the present invention provides:
  - [1] a method for determining a pig's resistance to an influenza virus, wherein the method comprises the step of detecting an 11-bp deletion in a swine Mx1 gene exon, wherein the deletion is from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
- [2] the method according to [1], comprising the steps of:
  - (a) preparing a DNA sample from a subject pig;
  - (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1; and
    - (c) determining the nucleotide sequence of the amplified DNA;
- 35 [3] the method according to [1], comprising the steps of:
  - (a) preparing a DNA sample from a subject pig;

- (b) digesting the prepared DNA with a restriction enzyme;
- (c) separating DNA fragments based on their size; and
- (d) comparing the sizes of detected DNA fragments with that of a control;
- [4] the method according to [1], comprising the steps of:

10

15

20

25

- (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
  - (c) digesting the amplified DNA with a restriction enzyme;
  - (d) separating DNA fragments based on their size; and
  - (e) comparing the sizes of detected DNA fragments with that of a control;
- [5] the method according to [1], comprising the steps of:
  - (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
  - (c) dissociating the amplified DNA into single strands;
  - (d) separating the dissociated single-stranded DNAs on a non-denaturing gel; and
- (e) comparing the gel mobility of the fractionated single-stranded DNAs with that of a control;
- [6] the method according to [1], comprising the steps of:
  - (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
- (c) determining the molecular weight of the DNA amplified in step (b) by mass spectrometry; and
  - (d) comparing the molecular weight determined in step (c) with that of a control;
- [7] the method according to [1], comprising the steps of:
  - (a) preparing a DNA sample from a subject pig;
- (b) amplifying a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
  - (c) preparing a substrate with an immobilized nucleotide probe;
  - (d) contacting the DNA prepared in step (b) with the substrate prepared in step (c);
- (e) determining the intensity of hybridization between the DNA and the nucleotide probe immobilized on the substrate; and
  - (f) comparing the intensity determined in step (e) with that of a control;
- 35 [8] the method according to [1], comprising the steps of:
  - (a) preparing a protein sample from a subject pig; and

- (b) determining the amount of a mutant swine Mx1 protein in the protein sample, wherein said mutant swine Mx1 protein is encoded by a nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp nucleotide sequence from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted;
- 5 [9] an oligonucleotide that is a PCR primer for the method for determining of [1], wherein the oligonucleotide is used to amplify a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1;
  - [10] an oligonucleotide comprising at least 15 nucleotides, and hybridizing to a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a DNA region that is a swine Mx1 gene exon and comprises a nucleotide sequence in which the nucleotide sequence from positions 1964 to 1974 has been deleted;
  - [11] an antibody recognizing a mutant swine Mx1 protein encoded by the nucleotide sequence of a swine Mx1 gene exon in which the nucleotide sequence from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted;
  - [12] a test reagent for determining a pig's resistance to an influenza virus, wherein the reagent comprises the oligonucleotide according to [9] or [10], or the antibody according to [11].

# 20 [Mode for Carrying Out the Invention]

[0021]

10

15

25

30

The present invention provides methods for determining pig resistance to an influenza virus, comprising the step of detecting an 11-bp deletion in an exon of the swine Mx1 gene, wherein the deletion is from position 2064 to position 2074 in the nucleotide sequence of SEQ ID NO: 1.

[0022]

The nucleotide sequence of the last exon of the Mx1 gene described above is shown in SEQ ID NO: 1, and the amino acid sequence of a protein encoded by the nucleotide sequence is shown in SEQ ID NO: 2. Those skilled in the art can readily obtain this sequence information using the PubMed Accession No. M65087.

[0023]

The "deleted" 11-bp of the present invention has the sequence of 5'-gg cgc cgg ctc-3' in the last exon of the Mx1 gene, and corresponds to the nucleotide region from positions 2064 to 2074 in SEQ ID NO: 1.

35 [0024]

In the present invention, a subject pig in which a heterozygous "11-bp deletion" as

described above has been detected in the last exon of its Mx1 gene, is judged to have an Mx1 protein with no ability to suppress influenza viruses. Alternatively, the cells of a subject pig carrying a homozygous "11-bp deletion" as described above are judged to have only an Mx1 protein with no ability to suppress influenza viruses, and thus the subject pig is judged to exhibit high susceptibility to influenza viruses. A subject pig is judged to be resistant to influenza viruses if the "11-bp deletion" described above is not detected.

[0025]

5

10

15

20

25

30

35

In the present invention, there are no limitations on the methods (means) for detecting the above-described "11-bp deletion" in the last exon of the swine Mx1 gene, as long as the methods (means) can detect a "deletion" as defined above. For example, such a method may comprise the step of directly determining the nucleotide sequence of the last exon containing the above-defined deletion portion in the Mx1 gene of a subject pig.

[0026]

In this method, first, a DNA sample is prepared from a subject pig. The DNA sample can be prepared from, for example, chromosomal DNA extracted from organs, tissues, cells, blood, oral mucosal membranes, skin, or hair of the subject pig, and alternatively cDNA or mRNA that contains no introns.

[0027]

Next step in the method involves isolating a DNA that is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1. The DNA can be isolated by PCR or such using chromosomal DNA or RNA as a template and using primers that hybridize to the last exon of the swine Mx1 gene. Then, the nucleotide sequence of the isolated DNA is determined. The nucleotide sequence of the isolated DNA can be determined by using methods known to those skilled in the art.

[0028]

In the next step of the method, the determined nucleotide sequence of the DNA is compared to that of a control. In this method, the control refers to the sequence of the normal (wild type) swine Mx1 gene (for example, SEQ ID NO: 1).

[0029]

Besides the methods which directly determine the nucleotide sequence of DNA derived from a subject pig as described above, different possible methods to determine the above-described "deletion" can also be used for the determination method of the present invention.

[0030]

For example, detection of the above-described "deletion" of the present invention can also be achieved using the method described below.

[0031]

5

10

15

20

25

30

35

First, a DNA sample is prepared from a subject pig. Then, the prepared DNA sample is digested with restriction enzymes. In the next step, DNA fragments are fractionated based on their size. The sizes of the detected DNA fragments are then compared with that of the control. In another embodiment, first, a DNA sample is prepared from a subject pig, followed by the amplification of a DNA that is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1. The amplified DNA is then digested with restriction enzymes. In the next step, DNA fragments are fractionated based on their size. The sizes of the detected DNA fragments are then compared with that of the control.

[0032]

Such methods include, for example, methods using Restriction Fragment Length Polymorphism (RFLP) and PCR-RFLP. Specifically, when a restriction enzyme recognition site is mutated (deleted), the fragment sizes yielded by restriction enzyme treatments are different from the control. The region containing the mutation is amplified by PCR, and digested with different restriction enzymes. The mutation can be detected based on the difference of band mobility in electrophoresis. Alternatively, chromosomal DNA is digested with these restriction enzymes and electrophoresed. The mutation can be detected by Southern blotting using a probe DNA of the present invention. Such restriction enzymes can be appropriately selected depending on the mutation. In this method, instead of genomic DNA, cDNA prepared from the RNA of a subject pig using reverse transcriptase can also be used. The cDNA can be directly digested with restriction enzymes and then analyzed by Southern blotting. Alternatively, the DNA which is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is amplified by PCR using the cDNA as a template, subjected to restriction enzyme treatments, and examined for differences in band mobility.

[0033]

In an alternative method, first, a DNA sample is prepared from a subject pig. Then, the DNA which is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is amplified. Then, the amplified DNA is dissociated into single-stranded DNAs. In the next step, the dissociated single-strand DNAs are fractionated on a non-denaturing gel. The electrophoretic mobility of the fractionated single-stranded DNAs is compared to that of the control.

[0034]

This method is exemplified by PCR-SSCP (single-strand conformation polymorphism; Cloning and polymerase chain reaction-single-strand conformation polymorphism analysis of

anonymous Alu repeats on chromosome 11. Genomics. 1992 Jan 1, 12(1), 139-146; Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene. 1991 Aug 1, 6(8), 1313-1318; Multiple fluorescence-based PCR-SSCP analysis with postlabeling. PCR Methods Appl. 1995 Apr 1, 4(5), 275-282). This method has advantages such as relatively simple operation and small amounts of sample required, and is thus particularly suitable for screening large quantities of DNA samples. The principle of the method is as follows. When a double-stranded DNA fragment is dissociated into single strands, each strand forms its own conformation depending on the nucleotide sequence. The dissociated DNA stands are electrophoresed on a polyacrylamide gel containing no denaturant. The complementary single-stranded DNAs which are identical in length move to different locations because of their conformational differences. Even with a single nucleotide substitution, the single-stranded DNA conformation is altered, resulting in different electrophoretic mobility in polyacrylamide gel electrophoresis. Thus, mutations such as deletions in a DNA fragment can be detected by determining the electrophoretic mobility.

[0035]

5

10

15

20

25

30

35

Specifically, first, the DNA which is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is amplified by PCR or the like. Generally, a preferred size of the PCR-amplified region ranges from about 200 to 400 bp. Those skilled in the art can appropriately select the PCR conditions and such. The amplified DNA products can be labeled by using PCR primers labeled with an isotope such as <sup>32</sup>P, fluorescent dye, biotin, or such. Alternatively, the amplified DNA products can be labeled using a PCR solution containing substrate nucleotides labeled with an isotope such as <sup>32</sup>P, fluorescent dye, biotin, or such. Alternatively, the amplified DNA fragments can be labeled by using the Klenow enzyme or such to add substrate nucleotides labeled with an isotope such as <sup>32</sup>P, fluorescent dye, biotin, or such after PCR is completed. The labeled DNA fragments are denatured by heating, and then electrophoresed on a polyacrylamide gel containing no denaturant such as urea. The conditions for separating the DNA fragments can be improved by adding an adequate amount of glycerol (about 5-10%) to the polyacrylamide gel. The electrophoresis conditions are appropriately selected depending on the properties of the respective DNA fragments. Typically, electrophoresis is carried out at room temperature (20-25°C). When the separation is insufficient, a temperature that gives optimal mobility is selected from 4 to 30°C. Following electrophoresis, the DNA fragments are analyzed for their mobility by autoradiography using X-ray film, fluorescence scanner, or the like. Bands that have differential mobility are identified, excised directly from the gel, amplified again by PCR and then sequenced directly. The presence of a mutation can be confirmed based on the sequence. Unlabeled DNA can also be used and detected as bands by staining the gel using

ethidium bromide, sliver staining, or the like, after electrophoresis is completed.

[0036]

5

10

15

20

25

30

35

In an alternative method, first, a DNA that is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1 is prepared from a subject pig, and a substrate is prepared to which nucleotide probes that hybridize to the DNA have been immobilized. Then, the DNA is contacted with the substrate. The "deletion" described above is detected by detecting the DNAs hybridized to the nucleotide probes immobilized on the substrate.

[0037]

Such a method is exemplified by DNA array. Methods known to those skilled in the art can be used to prepare from a subject pig, a DNA sample that is an exon of the swine Mx1 gene and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1. In a preferred embodiment, the DNA sample may be prepared from, for example, chromosomal DNA extracted from tissues or cells of skin, oral mucosal membranes, blood, or the like of a subject pig. The DNA sample to be used in the method described above can be prepared from chromosomal DNA as follows. A DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is prepared by, for example, PCR using chromosomal DNA as a template, and primers that hybridize to the DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1. The prepared DNA sample can be labeled for the convenience of detection using methods known to those skilled in the art, as necessary.

[0038]

Herein, the term, "substrate" refers to a plate-shaped material onto which nucleotides can be immobilized. Herein, the term "nucleotide" refers to both oligonucleotides and polynucleotides. There are no limitations on the substrate of the present invention, as long as nucleotides can be immobilized on it. Substrates routinely used in the DNA array technology can be used suitably in the present invention.

[0039]

Typical DNA array is composed of thousands of nucleotides densely printed on a substrate. Typically, these DNAs are printed on the surface of a non-porous substrate. The surface of a typical substrate is made of glass. However, it may be made of a porous membrane, for example, nitrocellulose membrane.

[0040]

Methods of immobilizing nucleotides (array) used in the present invention include the oligonucleotide-based array method developed by Affymetrix. Oligonucleotides used in the

oligonucleotide-based array are typically synthesized *in situ*. Any of the known methods of synthesizing oligonucleotides *in situ* based on, for example, the photolithography technology (Affymetrix) or ink-jet printing technology for immobilization of substances (Rosetta Inpharmatics), can be used to prepare the substrates of the present invention.

[0041]

5

10

15

20

25

30

35

There are no limitations on the nucleotide probe to be immobilized onto a substrate, as long as it can detect the above-described "deletion". Specifically, the probe includes, for example, probes hybridizing specifically to a DNA that is a wild-type swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a DNA that is a swine Mx1 gene exon in which the nucleotide sequence from positions 2064 to 2074 of the nucleotide sequence in SEQ ID NO: 1 have been deleted. As long as specific hybridization is possible, the nucleotide probe needs not be completely complementary to the DNA to be detected which is a wild-type swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064-2074 in the nucleotide sequence of SEQ ID NO: 1, or the DNA which is a swine Mx1 gene exon in which the nucleotide sequence from positions 2064 to 2074 of the nucleotide sequence in SEQ ID NO: 1 have been deleted.

[0042]

In the present invention, when oligonucleotides are immobilized, the length of a nucleotide probe to be bound to a substrate is typically 10-100 bases, preferably 10-50 bases, more preferably 15-25 bases.

[0043]

Next step in the present invention involves contacting a cDNA sample with the substrate. In this step, a DNA sample is hybridized to the above-described nucleotide probes. Hybridization solution and conditions vary depending on factors such as the length of the nucleotide probes to be immobilized onto the substrate; however, the hybridization can generally be carried out using methods known to those skilled in the art.

[0044]

Next step in the present invention involves determining whether the DNA sample is hybridized to the nucleotide probes immobilized on the substrate, and the intensity of the hybridization. This detection can be achieved by, for example, reading fluorescence signals using a scanner or such. In DNA array technology, DNA immobilized on a glass slide is generally referred to as the "probe", while labeled DNA in the solution is referred to as the "target". Therefore, the above-described nucleotides immobilized on the substrate are referred to as "nucleotide probes" herein.

[0045]

In addition to the methods described above, the allele specific oligonucleotide (ASO)

hybridization method can be used to detect deletions at a particular position. An oligonucleotide comprising a nucleotide sequence with potential mutations (deletions) is prepared, and hybridized with a sample DNA. Mutations in the DNA would result in a decrease in the efficiency of hybrid formation. The degree of hybridization can be determined by, for example, Southern blotting or methods using quenching resulting from the intercalation of a specific fluorescent reagent into the gaps of the hybrid. The ribonuclease A mismatch cleavage method can also be used. Specifically, a DNA that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is amplified by PCR or such. The amplified DNA is hybridized with a labeled RNA prepared from, for example, a cDNA of the last exon of the Mx1 gene incorporated into a plasmid vector. The hybrid has a partially single-stranded structure where the mutation is present. The single-stranded portion is cleaved by ribonuclease A, and detected using autoradiography or such. The mutation can be detected using the method described above.

[0046]

10

15

20

25

30

35

In an alternative method, first, DNA is prepared from a subject pig, and then a DNA which is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, is amplified. The amplified DNA is then analyzed by mass spectrometry to determine its molecular weight. The determined molecular weight is compared to that of a control. The method includes, for example, MALDI-TOF MS (Trends Biotechnol, 18, 77-84 (2000)).

[0047]

In another embodiment of the present invention, the above-described detection method is a detection method using the expression products of the last exon of the swine Mx1 gene as an indicator. Herein, the term "expression" refers to both transcription and translation.

Accordingly, the "expression products" include both mRNA and proteins.

[0048]

The present invention provides a method of assessing pigs that have resistance against influenza viruses, wherein the method comprises detecting expression products of the last exon of the swine Mx1 gene. In a preferred embodiment of the method, first, a protein sample is prepared from a subject pig, and then the amount of a mutant swine Mx1 protein contained in the sample is determined, wherein the mutant protein is encoded by the nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp segment from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted.

[0049]

Such a method includes SDS-polyacrylamide gel electrophoresis; and Western blotting, dot blotting, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), and

immunofluorescence method which use an antibody against a mutant swine Mx1 protein encoded by a nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp segment from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted.

[0050]

5

10

15

20

25

30

35

A subject pig is determined to be susceptible to influenza viruses, when a mutant swine Mx1 protein encoded by the nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp segment from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted, is detected using the method described above. In contrast, when the above-described mutant protein is not detected, a subject pig is determined to be resistant to influenza viruses.

[0051]

The detection method is not restricted to the various detection methods described above. [0052]

The present invention also provides test reagents to be used in the methods of the present invention for assessing pigs that have resistance to influenza viruses.

[0053]

In an embodiment, the reagent is a test reagent comprising an oligonucleotide of at least 15 nucleotides that hybridizes to a DNA region, which is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a DNA region which is a swine Mx1 gene exon and comprises a nucleotide sequence containing a deletion of positions 1964 to 1974.

[0054]

The oligonucleotide hybridizes specifically to a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a DNA region that is a swine Mx1 gene exon and comprises a nucleotide sequence containing a deletion at positions 1964 to 1974. Herein, the phrase "hybridizes specifically" means that there is no significant cross-hybridization between the oligonucleotide and DNAs encoding other proteins under standard hybridization conditions or preferably under stringent hybridization conditions (for example, the conditions described in Sambrook *et al.*, "Molecular Cloning", 2nd Ed., Cold Spring Harbor Laboratory Press, New York, USA, 1989). It is not necessary for an oligonucleotide to be completely complementary to the above-described nucleotide sequence to be detected, as long as it can hybridize specifically.

[0055]

The oligonucleotide can be used as a probe or primer in the detection methods of the present invention. When the oligonucleotide is used as a primer, its length is typically 15-100 bp, and preferably 17-30 bp. There are no limitations on the primer, as long as it allows the

amplification of a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1. Such primers include, though not limited to, for example, oligonucleotides comprising the sequence of SEO ID NO: 9 or 10 described below in the Example.

[0056]

5

10

15

20

25

30

35

Alternatively, when the oligonucleotide of the present invention is used as a probe, there are no limitations on the probe, as long as it hybridizes specifically to at least a portion of a DNA region that is a swine Mx1 gene exon and comprises the nucleotide sequence from positions 2064 to 2074 in the nucleotide sequence of SEQ ID NO: 1, or a portion of a DNA region that is a swine Mx1 gene exon and comprises a nucleotide sequence containing a deletion of positions 1964 to 1974. The probe can be a synthetic oligonucleotide, and is typically at least 15 bp long. [0057]

The oligonucleotides of the present invention can be prepared by, for example, using a commercially available oligonucleotide synthesizer. The probes can also be prepared as double-stranded DNA fragments from restriction enzyme treatments or the like.

[0058]

The oligonucleotides of the present invention can be suitably used as probes after proper labeling. The labeling method includes, for example, labeling methods that phosphorylate the 5' end of an oligonucleotide with <sup>32</sup>P using the T4 polynucleotide kinase; methods such as the random primer method, in which substrate nucleotides labeled with an isotope such as <sup>32</sup>P, fluorescent dye, biotin, or such are incorporated into DNA, by using a primer such as random hexamer oligonucleotide or the like, and a DNA polymerase such as the Klenow enzyme.

[0059]

In another embodiment, the test reagent of the present invention is a reagent comprising an antibody against a mutant swine Mx1 protein encoded by the nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp segment from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted. There are no limitations on the antibodies of the present invention, as long as they can be applied to the methods of this invention. Such an antibody includes, for example, polyclonal and monoclonal antibodies. The antibody may be labeled as necessary.

[0060]

The antibodies against a mutant swine Mx1 protein encoded by the nucleotide sequence that is a swine Mx1 gene exon in which the 11-bp segment from positions 2064 to 2074 in SEQ ID NO: 1 has been deleted, can be prepared by methods known to those skilled in the art. Polyclonal antibodies can be prepared by the procedure described below. Small animals such as rabbits are immunized with a mutant swine Mx1 protein, or a recombinant mutant swine Mx1 protein or a partial peptide thereof, obtained by expressing its GST fusion protein in

microorganisms such as E. coli. Sera collected from the animals are purified, for example, by using ammonium sulfate precipitation, protein A column, protein G column, DEAE ion exchange chromatography, or affinity column coupled with the mutant swine Mx1 protein or synthetic peptide. Monoclonal antibodies can be prepared by, for example, immunizing a small animal such as mouse with a mutant swine Mx1 protein or a partial peptide thereof, extracting and gently crushing the mouse spleen to isolate cells. The cells obtained are fused with mouse myeloma cells using reagents such as polyethylene glycol. From these fused cells (hybridoma), clones producing antibodies that bind to the mutant swine Mx1 protein are selected. Next, the resulting hybridomas are transplanted into the peritoneal cavity of a mouse, from which ascites is collected. The monoclonal antibody prepared is purified by, for example, using ammonium sulfate precipitation, protein A column, protein G column, DEAE ion exchange chromatography, affinity column coupled with the mutant swine Mx1 protein or synthetic peptide.

[0061]

The test reagent described above may contain, in addition to an oligonucleotide or antibody as the active ingredient, sterilized water, physiological saline, a vegetable oil, a detergent, a lipid, a solubilizing agent, a buffer, a protein stabilizer (BSA, gelatin, etc.), a preservative, or such, as necessary.

## [Examples]

5

10

15

20

25

30

35

[0062]

Herein below, the present invention will be specifically described using Examples, however, it is not to be construed as being limited thereto.

[0063]

It was examined whether or not the Mx1 gene mutations identified in the swine breeds Meishan and Landrace had an impact on the function of the expressed protein.

[0064]

Specifically, whether or not the Mx1 gene mutations affect the defense function against infection was examined by carrying out experiments to infect cells harboring a forced-expressed normal or mutant Mx1 gene with an influenza virus.

[0065]

[Example 1] cDNA cloning of normal and mutant Mx1 genes from Meishan and Landrace pigs 5 ml of EDTA blood was collected from each of the 39 Meishan pigs and 36 Landrace pigs. The blood samples were diluted twice with RPMI 1640 (GIBCO), overlaid on Ficoll-Paque (Pharmacia Biotech), and then centrifuged at 400x g for 40 minutes. The layer containing lymphocytes was collected, and the cells were washed three times with phosphate buffered saline. The prepared lymphocytes were treated with DNAZol Reagent (GIBCO) for

DNA purification. PCR amplification was performed using the purified DNAs as a templates at conditions of 5 minutes at 94°C; 40 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 1 minute at 72°C; and 5 minutes at 72°C. Exon 13 was amplified from the DNA from Meishan pigs using a primer pair: 5'-CTGAAAGATCTCGGCTATGGAGG-3'/SEQ ID NO: 3; and

5'-AAGAAGCTGAGACGTCGATCCGGCT-3'/SEQ ID NO: 4. The last exon was amplified from the DNA from Landrace pigs using the primer pair

5'-AAGCGCATCTCCAGCCACATC-3'/SEQ ID NO: 5; and

5'-AAGACATTGGGCGTGAAAGG-3'/SEQ ID NO: 6.

The presence of the mutation in exon 13 was determined by direct sequencing. The presence of the mutation in the last exon was determined by examining the RFLP after Nal I treatment at 37°C for 2 hours.

[0066]

5

10

15

20

25

30

35

20 ml of EDTA blood was collected from animals that had been identified to carry a normal or mutant Mx1 gene. Lymphocytes were prepared from the blood, and suspended in RPMI 1640 containing 10% fetal bovine serum (FBS). The cell suspensions were incubated in a  $CO_2$  incubator at 37°C overnight. The cells were treated with 500 U human IFN $\alpha$ (Calbiochem) for three hours. RNAs were purified from the treated lymphocytes. The Mx1 gene was amplified by RT-PCR using the RNAs as templates and the primer pair AttB1mxF (5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTGTCACAGCGTCAAAGAAAAAGGAAG-3'/SEQ ID NO: 7) and attB2mxR (5'-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTTCTATGATGCTATGCGG-3'/SEQ ID NO: 8). The PCR products were combined with the pDONR201 vector from Gateway Cloning Technology (GIBCO). The mixtures were treated with BP Clonase (GIBCO) at 25°C for one hour. The BP reaction solution was combined with DH5α competent cells for transformation in a routine fashion, and selection of transformants was performed using LB plates containing 50 μg/ml kanamycin. The nucleotide sequence of the insert in each clone was determined by direct sequencing of PCR products obtained by colony PCR using attB1mx-F and attB2mx-R (2 minutes at 94°C; 30 cycles of 30 seconds at 94°C, 30 seconds at 64°C, and 3 minutes at 72°C; 5 minutes at 72°C). Normal Mx1 cDNA clone is referred to as pEntmx1, Meishan cDNA clone is referred to as pEntmx1-3, and Landrace cDNA clone is referred to as pEntmx1-11.

[0067]

[Example 2] Construction of Mx1 gene expression vectors

Each of the recombinant clones, pEntmx1, pEntmx1-3, and pEntmx1-11, was inoculated into 15 ml of LB, cultured while shaking at 37°C overnight, and the plasmid DNAs were purified by the alkaline isolation method. The plasmid DNAs were combined with pDEST12.2 (GIBCO). After treatment with LR Clonase (GIBCO) at 25°C for 60 minutes, the DNAs were

transformed into DH5 $\alpha$  competent cells. The selection of transformants was performed using LB containing 100 µg/m ampicillin. Plasmid DNAs were purified from the respective recombinant clones, which are designated as pExmx1, pExmx1-3, and pExmx1-11. The nucleotide sequence of the insert in each clone was determined by direct sequencing of PCR products obtained by colony PCR using attB1mx-F and attBmx-R.

[8800]

5

10

15

20

25

30

35

[Example 3] Preparation of Mx1 gene transformants

NIH3T3 cells were passaged and maintained using Dulbecco's modified MEM (DMEM, GIBCO) containing 7% FBS. 5  $\mu$ g of pExmx1, pExmx1-3, and pExmx1-11 was each combined with 0.4 ml of 3T3 cell suspension (4x  $10^6$  cells), placed in 2-mm-thick cuvettes, and electroporated at 100  $\mu$ F, 13 ohm, 200 v, and 1 kv/cm. After incubation for four days, the cells were cultured in DMEM containing 500  $\mu$ g/ml G418 (Geneticin; GIBCO) for the selection of transformants. The pExmx1 transformant is designated as 3T3-0, pExmx1-3 transformant as 3T3-3, and pExmx1-11 transformant as 3T3-11.

[0069]

[Example 4] Preparation of influenza virus particles

An influenza virus (Aichi; H2N2) was inoculated into the allantoic cavities of 11-day-old SPF eggs. The eggs were incubated at 37°C for two days, and then allowed to stand overnight at 4°C. Allantoic fluids were collected from the eggs, and then centrifuged at 3500 rpm for 20 minutes. Aliquots of the supernatant (seed virus solution) were stored at -80°C. The titer of seed virus was estimated to be 107.5 EID<sub>50</sub> (50% Egg-Infective Dose)/0.2 ml.

[0070]

[Example 5] Influenza virus infection experiments

Whether forced expression of each Mx1 gene type has an impact on the viral propagation was examined by varying the virus dose used for infection.

[0071]

3T3, 3T3-0, 3T3-3, and 3T3-11 cells were prepared at a cell density of 5x 10<sup>4</sup> cells/ml. 1 ml of each cell suspension was added to the wells of a 24-well plate. The cells were incubated in a CO<sub>2</sub> incubator at 37°C for two days, and washed once with phosphate buffered saline (PBS). The seed virus solution was diluted 1:10 (corresponding to MOI (multiplicity of infection) =10) and 1:100 (corresponding to MOI =1) in PBS. The cells were inoculated with the diluted viral solutions, and incubated for adsorption at 37°C for one hour. Unadsorbed virus was removed by washing the cells twice with PBS. 2 ml of DMEM was added to the cells, and the cells were then incubated. Sampling was carried out at 0, 6, 12, 18, 24, 30, 36, 48, and 54 hours. The collected culture supernatants were centrifuged at 2500 rpm for 5 minutes. The supernatants were stored at -80°C until they were assayed for viral titer.

[0072]

Viral titers in the supernatants collected over time were determined as described below. Serial 1:10 dilutions of each viral solution were prepared in PBS. 0.2 ml of each diluted viral solution was inoculated into the allantoic cavities of two 11-day-old eggs. After incubation for two days, the eggs were allowed to stand at 4°C overnight. The allantoic fluids were analyzed for hemagglutinating activity.

[0073]

10

15

20

25

30

At MOI=1, the release of propagating virus into culture supernatants was recorded 18 hours after virus infection, and reached its peak of 2.8-3.0 EID<sub>50</sub>/0.2 ml in 36 hours in the case of 3T3 and 3T3-11 cells. On the other hand, 3T3-0 and 3T3-3 cells have 1.0 EID<sub>50</sub>/0.2 ml of propagating virus after 36-48 hours. However, no further increase in the viral propagation was recorded. Thus, the virus propagation was clearly different from that observed with the 3T3 and 3T3-11 cells (Fig. 2).

[0074]

In the case of the 3T3 and 3T3-11 cells, at MOI=10, 0.3-0.5  $\rm EID_{50}/0.2$  ml of infectious virus was detected in culture supernatants 12 hours after virus infection, and the viral titer reached its peak of 4.5-4.7  $\rm EID_{50}/0.2$  ml in 36 hours. On the other hand, when 3T3-0 and 3T3-3 cells were used, the titer of infectious virus was 0.5  $\rm EID_{50}/0.2$  ml after 24 hours, 2.7-2.8  $\rm EID_{50}/0.2$  ml after 48 hours, and no further increase in the viral propagation was recorded after that. Thus, the viral propagation was evidently suppressed (Fig. 3).

[0075]

Influenza virus is an RNA virus. Therefore, there is a possibility that the infection of 3T3 cells may result in the production of mouse IFN $\alpha$ , which affects viral propagation. Accordingly, another infection experiment was carried out, in which cells of each 3T3 cell type were infected with the virus at MOI=10, passaged and maintained in culture media containing anti-mouse IFN $\alpha$  for 12 days. Sampling was carried out after 36 hours. The viral titers in the culture supernatants were determined, and the results showed that the degree of viral propagation was comparable to that with cell groups that had not been treated with anti-mouse IFN $\alpha$ . This suggests that the factor affecting viral propagation is the introduced swine Mx1 gene.

[0076]

[Example 6] Comparison of Mx1 expression levels in transformed cells

To examine whether the difference in viral propagation reflects the level of Mx1 expression in the respective types of cells, RT-PCR was performed using RNAs extracted from the respective types of cells used in the infection experiments.

35 [0077]

3T3, 3T3-3, and 3T3-11 cells were prepared at a cell density of 2x 10<sup>6</sup> cells/ml. RNAs

were extracted and purified from the cells, and the Mx1 expression levels were determined by RT-PCR. The primer pair AttB1mxF and AttB2mxR was used. The PCR conditions were: 30 minutes at 55°C; 2 minutes at 94°C; 40 cycles of 15 seconds at 94°C, 30 seconds at 58°C, and 3 minutes at 68°C; 5 minutes at 72°C for extension. For external standard quantification, mouse G3PDH (TOYOBO) was amplified and used as a positive control for the expression level. A reaction solution to which distilled water was added instead of the template DNA was used as a negative control.

[0078]

5

10

15

20

25

30

35

According to the results obtained, while the swine Mx1 gene was not expressed in 3T3 cells (lane 1 in Fig. 4), the expression of the swine Mx1 gene was detectable in 3T3-0, 3T3-11, and 3T3-3 cells (lanes 3, 4 and 5 in Fig. 4), and slightly higher in 3T3-11 cells. The expression level of the internal standard mouse G3PDH suggested that the numbers of collected cells did not differ substantially among the respective cell types, and thus the levels of the Mx1 protein produced in 3T3-0, 3T3-11, and 3T3-3 cells were comparable to each other.

[0079]

[Example 7] Detection of an 11-base deletion in the last exon of swine Mx1 gene by PCR amplification

The following primer set was used in PCR for the subject pigs. The portion to be amplified was at positions 1981 to 2160 in the sequence of PubMed accession No. M65087 (Fig. 5).

Primer F: 5'- AGT GAC AGG AGC GAC AAG AG -3' (SEQ ID NO: 9)
Primer R: 5'- CCT GGA GAG TCC GGT TCA -3' (SEQ ID NO: 10)
[0080]

PCR conditions were: 1) 10 minutes at 94°C; 2) 30 seconds at 94°C, 30 seconds at 60°C, and 1 minute at 72°C; 3) 5 minutes at 72°C. Then, 2 µl of the PCR products was electrophoresed on a 6 % polyacrylamide gel at 200 V for 1 hour. The gel was sliver stained (Fig. 6). The wild type PCR product had a size of 105 bp. The 11-bp deletion product has a size of 94 bp. The size marker used was fX174/HaeIII.

[0081]

As seen in Fig. 6, the 11-bp deletion could be detected by PCR using the above-described primer pair.

[Effects of the Invention]

[0082]

Among domestic pigs used worldwide, there are some that carry an Mx1 gene containing a 11-bp deletion which results in the loss of the ability to suppress viral propagation.

Such animals are expected to have a serious defect in their defense ability during the early phase of an RNA virus invasion.

[0083]

5

10

15

20

25

[Simplified procedures for determining genetic disease resistance]

Animals carrying the wild-type gene which confers virus-suppressing ability can be selected from such pig populations, by collecting a small amount of DNA-containing tissues such as flesh and hair root, or blood, and using the extracted DNA to determine genotypes of the Mx1 gene, which is the subject of interest in the present invention. Alternatively, animals comprising undesired genotypes can be eliminated.

[0084]

[Improved pig production]

The level of genetic resistance to diseases caused by RNA viruses, including influenza viruses, can be studied according to the present invention. Healthy animals which are more favorable for pig production can be selected based on the information. Furthermore, the incidence of respiratory diseases in piglets can be reduced, leading to increases in the survival and growth rates.

[0085]

[For human health]

Pig populations with impaired ability to suppress influenza virus propagation are susceptible to influenza infection. Unless all of the pigs die, the influenza virus will propagate and undergo genetic mutations, and in some cases evolve into new strains of influenza virus. Like the influenza virus that caused the Spanish influenza epidemic between 1917-1918, resulting in more than 40 million deaths around the world and more than 300,000 deaths in Japan alone, a new strain of influenza virus can cause enormous damage if it infects humans. By selecting pigs with a high ability to suppress influenza virus propagation according to the present invention, the propagation of an influenza virus can be suppressed in pig populations, thereby reducing the chance of the emergence of new influenza virus strains, and raising the possibility of eliminating one threat against humans.

```
[0086]
```

## [Sequence Listing]

<110> National Institute of Agrobiological Sciences

5 <120> Method to estimate the inherited resistance and susceptibility to RNA virus disease in pigs

<130> MOA-A0214

<140>

10 <141>

<160> 10

<170> PatentIn Ver. 2.1

15

⟨210⟩ 1

<211> 2545

<212> DNA

<213> Sus scrofa

20

<220>

<221> CDS

⟨222⟩ (101).. (2092)

25 <220>

<221> polyA\_signal

<222> (2517).. (2522)

⟨400⟩ 1

30 gtaagtgtgg gagaacagcc ctgcatttct gctgacgggt caacgtcaca gcgtcaaaga 60

aaaggaaggt acatttcagc tgaactgatc aaggaggaag atg gtt tat tcc agc 115

Met Val Tyr Ser Ser

1 5

35

tgt gaa agt aaa gaa cct gat tca gtt tct gca tcc aat cac ctg tta 163

	Cys	Glu	Ser	Lys	Glu	Pro	Asp	Ser	Val	Ser	Ala	Ser	Asn	His	Leu	Leu	
					10					15					20		
	cta	aat	ggg	aat	gat	gaa	ttg	gtg	gag	aaa	agt	cac	aaa	aca	ggg	cct	211
5	Leu	Asn	Gly	Asn	Asp	Glu	Leu	Val	Glu	Lys	Ser	His	Lys	Thr	Gly	Pro	
				25					30					35			
	gag	aac	aac	ctg	tac	agc	cag	tac	gag	gag	aaa	gtg	cgg	ccc	tgc	atc	259
	Glu	Asn	Asn	Leu	Tyr	Ser	Gln	Tyr	Glu	Glu	Lys	Val	Arg	Pro	Cys	Ile	
0			40					45					50				
		•															
	gac	ctc	atc	gac	tca	ctg	cgg	gcc	ctg	ggc	gtg	gag	cag	gac	ctg	gcc	307
	Asp	Leu	Ile	Asp	Ser	Leu	Arg	Ala	Leu	Gly	Val	Glu	Gln	Asp	Leu	Ala	
		55					60					65					
15																	
	ctg	ccc	gcc	atc	gcc	gtc	atc	ggg	gac	cag	agt	tcg	ggc	aag	agc	tcc	355
	Leu	Pro	Ala	Ile	Ala	Val	Ile	G1y	Asp	Gln	Ser	Ser	Gly	Lys	Ser	Ser	
	70	•				75					80					85	
20								gtc									403
	Val	Let	ı Glu	ı Ala	Leu	ı Ser	Gly	Val	Ala			Arg	Gly	Ser			
					90	)				95	5				100	1	
																	451
																gaa	
25	Va]	l Thi	r Arg			) Leu	ı Val	Leu			ı Lys	s Lys	: Lei			Glu	
				105	5				110	)				115	)		
										,							400
																gag	
••	Glı	ı As			o Ly:	s Gly	7 Lys			· 1 y 1	r Arg	g As			1 116	e Glu	
30			120	0				125	)				130	J			
														. ~~		++	547
																g att	
	Lei			p Ala	a Se	r Gli			ı Lys	s ՄII	и va.			a Ali	a GII	n Ile	•
2.5		13	5				140	U				14	J				
35				<b>.</b>			~ <i></i> +		+-		t cc:	+ ~~	a ot	a a+	n an	t cto	g 59!
	gc	c at	c gc	τgg	g ga	a gg	gt	g gg	1 al(	ag د	ı ca	r ga	g CL	aai	c ag	t ctg	5 030

	Ala	Ile	Ala	Gly	Glu	Gly	Val	Gly	Ile	Ser	His	Glu	Leu	Ile	Ser	Leu	
	150					155					160					165	
•	gag	gtc	agc	tcc	cct	cat	gtc	cca	gat	ctg	acc	ctc	aţa	gac	ctt	cct	643
5			Ser														
5	Glu	Val	261	961		1113	141	110	пор	175	1111	204		<u>F</u>	180		
					170					110					100		
						4	_+_		+	~~~		+00	<b>~</b> 00	ato	naa	tac	691
			acc														031
	Gly	lle	Thr		Val	Ala	Val	Gly		GIN	Pro	lyr	ASP		Giu	1 9 1	
10				185					190					195			
	cag	atc	aag	tct	ctg	atc	aag	aag	tac	atc	tgt	aag	cag	gag	acc	atc	739
	Gln	Ile	Lys	Ser	Leu	Ile	Lys	Lys	Tyr	Ile	Cys	Lys	Gln	Glu	Thr	Ile	
			200					205					210				
15																	
	aac	ttg	gtg	gtg	gtc	ccc	tgt	aac	gtg	gac	att	gcc	acc	acg	gag	gcg	787
	Asn	Leu	. Val	Val	Val	Pro	Cys	Asn	Val	Asp	Ile	Ala	Thr	Thr	Glu	Ala	
		215	;				220					225					
20	ctg	cgo	atg	gcc	cag	gag	gtg	gac	ccc	gaa	gga	gac	agg	acc	ato	ggg	835
																Gly	
	230		,			235		_			240					245	
	200																
	a+a	. ++.				r ast	. eta	ata	ເຜລດ	999		· act	. 000	, ga	. ลลด	g ata	883
25																	000
25	116	e Lei	ıını	Lys			) Leu	l vai	. Asp			, 1111	. 010	i Aloj	260	i Ile	
					250	)				255	)				200	,	
																	001
																atg	931
	Va]	l As	p Val	l Ala	a Arg	g Asr	ı Let	ı Val	l Phe	His	s Lei	ı Ly:	s Lys	s Gl	у Тул	r Met	
30				26	5				270	)				27	5		
	ati	t gt	c aag	g tg	c ag	g ggo	c cag	g cag	g gad	c ato	ca	g ga	g cas	g ct	g ag	c ctg	979
	I16	e Va	l Ly:	s Cy	s Ar	g Gl	y Glı	ı Glı	n Asp	o Ile	e Gl	n Gl	u Gli	n Le	u Se	r Leu	
			280	0				28	5				290	0			
35																	
	gri	c aa	g gr	c.ct	g ca	g aa	g gas	g ca	g gco	e tte	c tt	t ga	a aa	c ca	c gc	a cat	1027
	50	- ua	0 50		0 00	u.	0 0 - 0	,	J 35.						•		

	Ala Lys	Ala	Leu	Gln	Lys	Glu	Gln	Ala	Phe	Phe	Glu	Asn	His	Ala	His	
	295					300					305					
	ttc agg	gat.	ctt	ctg	gag	gaa	ggg	cgg	gcc	acg	atc	ccc	tgc	ctg	gca	1075
5	Phe Arg															
	310	•			315		_			320					325	
	gaa aga	ctg	acc	tct	gaa	ctc	atc	atg	cac	atc	tgt	aaa	act	ctg	ccc	1123
	Glu Arg	Leu	Thr	Ser	Glu	Leu	Ile	Met	His	Ile	Cys	Lys	Thr	Leu	Pro	
10				330					335					340		
	ctg tta															1171
	Leu Leu	Glu			Ile	Lys	Glu		His	Gln	Lys	He			GIU	
1.5			345					350					355			
15	tta cag	000	tat	aao	too	nat	att	cca	asa	σat	ซลล	age	σσσ	ลลต	atø	1219
	Leu Gln															
	Dea oin	360		01,	501		365					370		•		
20	ttt ttt	ctg	ata	gat	aaa	atc	gat	gca	ttt	aat	agt	gat	ato	act	gct	1267
	Phe Phe	Leu	ı Ile	Asp	Lys	Ile	Asp	Ala	Phe	Asn	Ser	Asp	Ile	Thr	Ala	
	375	;				380	1				385	;				
																_
	ttg ata															1315
25	Leu Ile	Glr	Gly	Glu			ı Val	Val	Glu			ı Cys	Arg	g Let		
	390				395	i				400	)				405	
			- 000			. ++.			taa	r agt	t act	- ata	ratt	- 022	990	1363
	acc aag Thr Lys															1000
30	IIII Lyc	, mc	, 111 E	410			, 0, 1	, ,,,,	415					420		
50																
	aat tto	c aaa	a aat	t ggt	tat	gao	c gcc	ata	ı tgt	aaa	a caa	a ato	cas	g cto	c ttc	1411
	Asn Phe	e Lys	s Ası	n Gly	Ту1	: Ası	o Ala	ı Ile	e Cys	Ly:	s Glı	n Ile	e Glı	n Lei	ı Phe	
			42	5				430	)				43	5		
35																
	gaa aa	t ca	g ta	c agg	g ggg	g aga	a gag	g ttg	g cca	a gg	g tt	t gtį	g aa	t ta	t aag	1459

	Glu	Asn	Gln	Tyr	Arg	Gly	Arg	Glu	Leu	Pro	Gly	Phe	Val	Asn	Tyr	Lys	
			440					445					450				
	aca	ttt	gaa	acc	atc	att	aag	aag	cag	gtc	agt	gtc	ctg	gaa	gag	cca	1507
5	Thr	Phe	Glu	Thr	Ile	Ile	Lys	Lys	Gln	Val	Ser	Val	Leu	Glu	Glu	Pro	
		455					460					465					
	gcc	gtg	gac	atg	ctg	cac	aca	gtg	act	gat	tta	gtc	cgg	ctc	gcc	ttc	1555
	Ala	Val	Asp	Met	Leu	His	Thr	Val	Thr	Asp	Leu	Val	Arg	Leu	Ala	Phe	
10	470					475					480					485	
										gaa							1603
	Thr	Asp	Val	Ser	Glu	Thr	Asn	Phe	Asn	Glu	Phe	Phe	Asn	Leu			
					490					495					500		
15																	4054
																gaa	1651
	Thr	Ala	Lys			Ile	Glu	Asp			Leu	Glu	Gln			Glu	
				505					510					515	•		
																	1000
20																tac T	1699
	Ala	Glu			lle	Arg	Leu			Gin	Met	Glu			val	Tyr	
			520	l				525	•				530				
					_4_	4.4				+.			. «+«	0.00			1747
25																aag	1171
25	Cys			GIN	ı vaı	. lyr	540		, VIS	Leu	GII	545		. nie	GIC	ı Lys	
		535	,				540	,				OTO	,				
	a a a		, пос	n n a a		990		· 909	999	tca	เลลเ	: cas	tac	: t.t.1	t cts	g tcg	1795
																ı Ser	
30	550		· OIL	. 010	. 010	555		8	, 2, 2	, 501	560		,-			565	
50	000					000											
	tes	7 009	ም ምርር	2 000	ter	e tea	a gad		e tee	ata	gco	e gas	g ato	: tt	t ca	g cac	1843
																n His	
	501				570					575					586		
35																	
	cte	g att	t gco	c tac	c cat	t car	g gas	g gte	c ggo	c aas	g cgo	c at	c tc	c ag	c ca	c atc	1891
	5 5 5	,	- 35						55								

	Leu Ile Ala Tyr His	Gln Glu Val	Gly Lys Arg Ile Ser Ser His Ile	
	585	:	590 595	
				020
_	-		366 111 111 866 114 0	1939
5	600	605	Leu Arg Thr Phe Gly Gln Gln Leu 610	
	600	000	010	
	cag aag agc atg ctg	cag ctg ctg	cag aac aag gac caa tac gac tgg 1	1987
			Gln Asn Lys Asp Gln Tyr Asp Trp	
10	615	620	625	
	ctc ctg agg gag cgc	agt gac acc	agc gac aag agg aag ttc ctg aag 2	2035
	Leu Leu Arg Glu Arg	Ser Asp Thr	Ser Asp Lys Arg Lys Phe Leu Lys	
	630	635	640 645	
15				0000
			6-1-100 0 00 0	2083
	Glu Arg Leu Met Arg		Ala Arg Arg Arg Leu Ala Lys Phe 655 660	
	000		000	
20	cca ggc tga accggac	tct ccaggcgg	c cggggtctcc agggcacgtc	2132
	Pro Gly			
	tccaggcaac gaggacca	ac ctccttccct	aacagactag catcatgagc tcctgtttcg	2192
25	cacatectee tgtggtta	gt agactctaa	a gccaccgtcc ctgctgttag tggctgagga	2252
	cttagcaaga agctgtga	ta agcacgctg	g ctgcaagcat caggccattt acttgaatga	2312
				0270
20	gccccgccaa cgcttcg	ct cccgcgcct	c tetecatece tetetecate etteteteca	4314
30	tocctatata ggatacti	at coccacata	g catcatagaa gggtcattct ggtttctgta	2432
	teeetgtata ggataetg	561 000050404	S careatague BBB contract BB contraction	
	caagcettte aegeeca	itg tottagggg	c attacagcca cctgtgtgga tggatgcaca	2492
35	tagaagccta tttcttt	at ttgtaataa	a cttggttcta ccagcaaaaa aaa	2545

⟨210⟩ 2 <211> 663 <212> PRT <213> Sus scrofa ⟨400⟩ 2 Met Val Tyr Ser Ser Cys Glu Ser Lys Glu Pro Asp Ser Val Ser Ala Ser Asn His Leu Leu Leu Asn Gly Asn Asp Glu Leu Val Glu Lys Ser His Lys Thr Gly Pro Glu Asn Asn Leu Tyr Ser Gln Tyr Glu Glu Lys Val Arg Pro Cys Ile Asp Leu Ile Asp Ser Leu Arg Ala Leu Gly Val Glu Gln Asp Leu Ala Leu Pro Ala Ile Ala Val Ile Gly Asp Gln Ser Ser Gly Lys Ser Ser Val Leu Glu Ala Leu Ser Gly Val Ala Leu Pro Arg Gly Ser Gly Ile Val Thr Arg Cys Pro Leu Val Leu Lys Leu Lys Lys Leu Val Asn Glu Glu Asp Glu Trp Lys Gly Lys Val Ser Tyr Arg Asp Ser Glu Ile Glu Leu Ser Asp Ala Ser Gln Val Glu Lys Glu Val Ser Ala Ala Gln Ile Ala Ile Ala Gly Glu Gly Val Gly Ile Ser His 

	Glu	Leu	Ile	Ser	Leu 165	Glu	Val	Ser	Ser	Pro 170	His	Val	Pro	Asp	Leu 175	Thr
5	Leu	Ile	Asp	Leu 180	Pro	Gly	Ile	Thr	Arg 185	Val	Ala	Val	Gly	Asn 190	Gln	Pro
10	Tyr	Asp	Ile 195	Glu	Tyr	Gln	Ile	Lys 200	Ser	Leu	Ile	Lys	Lys 205	Tyr	Ile	Cys
10	Lys	Gln 210	Glu	Thr	Ile	Asn	Leu 215		Val	Val	Pro	Cys 220	Asn	Val	Asp	Ile
15	Ala 225	Thr	Thr	Glu	Ala	Leu 230	Arg	Met	Ala	Gln	Glu 235	Val	Asp	Pro	Glu	Gly 240
	Asp	Arg	Thr	Ile	Gly 245		Leu	Thr	Lys	Pro 250	Asp	Leu	Val	Asp	Lys 255	
20	Thr	Glu	Asp	Lys 260		Val	Asp	Val	Ala 265		g Asn	Leu	Val	Phe 270		Leu
25	Lys	Lys	Gly 275		· Met	Ile	Val	Lys 280		Arg	g Gly	Gln	Gln 285		lle	Gln
25	Glu	Gln 290		ı Sei	Leu	ı Ala	Lys 295		ı Leu	ı Glr	n Lys	300		Ala	Phe	Phe
30	Glu 305		n His	s Ala	a His	310		g Asp	Leu	ı Leı	315		ı Gly	Arg	g Ala	Thr 320
	Ile	Pro	c Cys	s Lei	ı Ala 329		ı Arş	g Lei	ı Thi	330		ı Leu	ı Ile	e Met	t His	s Ile
35	Cys	Lys	s Thi	r Lei	u Pro	Leı	ı Le	u Glı	u Ası	n <b>G</b> 1:	n Ile	e Lys	s Glu	ı Se	r His	s Gln

	Lys	Ile	Thr	Glu	Glu	Leu	Gln		Tyr	Gly	Ser	Asp		Pro	Glu	Asp
			355					360					365			
5	Glu		Gly	Lys	Met	Phe		Leu	Ile	Asp	Lys		Asp	Ala	Phe	Asn
		370					375					380				
		Asp	Ile	Thr	Ala		Ile	Gln	Gly	Glu		Leu	Val	Val	Glu	Tyr 400
10	385					390					395		-			400
	Glu	Cys	Arg	Leu	Phe 405	Thr	Lys	Met	Arg	Asn 410	Glu	Phe	Cys	Arg	Trp 415	Ser
					100					110					110	
15	Ala	Val	Val	Glu 420	Lys	Asn	Phe	Lys	Asn 425	Gly	Tyr	Asp	Ala	Ile 430	Cys	Lys
15				100												
	Gln	Ile	Gln 435		Phe	Glu	Asn	Gln 440	Tyr	Arg	Gly	Arg	Glu 445		Pro	Gly
																_
20	Phe	Val 450	Asn	Tyr	Lys	Thr	Phe 455		Thr	Ile	lle	Lys 460	Lys	Gln	Val	Ser
	** 1	<b>T</b>	0.1	01	ъ	4.7	77 7	•	16 - 4	T	. 11.5 _	Tl	V - 1	TL		I
	Val 465		i Glu	Glu	Pro	470		. Asp	мет	Leu	475		val	ınr	ASP	Leu 480
25	W_1	A		. 41.	Db	Tha	. Aan	. Vol	Som	. Clu	. ፐኬም	. Aan	Dha	. Aan	Glu	Pho
	Val	ALE	, Leu	i Ala	485		ust	, vai	. Der	490		USII	. 1110	, 11311	495	Phe
	Pho	Λar	ı laı	ı Hic	. Ara	. Thr	· Ala	Lvs	: Ser	Lvs	: Ile	. Gl11	Asr	. Ile	Lvs	Leu
30	1116	1151	I DCC	500		,	1110		505		, 110	010		510		
	Glu	ı Glr	n Glu	ı Lvs	: Glu	ı Ala	a Gli	ı Thr	Ser	· Ile	e Arg	Leu	ı His	s Phe	e Gln	Met
			515					520					525			
35	Glu	ı Glı	ı Ile	e Val	Туі	- Cys	s Glı	n Asp	Glr	n Val	l Tyr	. Arg	g Gly	7 Ala	ı Let	ı Gln

Lys Val Arg Glu Lys Glu Ala Glu Glu Glu Lys Asn Arg Lys Ser Asn 545 550 555 560

5 Gln Tyr Phe Leu Ser Ser Pro Ala Pro Ser Ser Asp Pro Ser Ile Ala 565 570 575

Glu Ile Phe Gln His Leu Ile Ala Tyr His Gln Glu Val Gly Lys Arg 580 585 590

10

15

Ile Ser Ser His Ile Pro Leu Ile Ile Gln Phe Phe Ile Leu Arg Thr
595 600 605

Phe Gly Gln Gln Leu Gln Lys Ser Met Leu Gln Leu Gln Asn Lys
610 615 620

Asp Gln Tyr Asp Trp Leu Leu Arg Glu Arg Ser Asp Thr Ser Asp Lys 625 630 635 640

20 Arg Lys Phe Leu Lys Glu Arg Leu Met Arg Leu Thr Gln Ala Arg Arg 645 650 655

Arg Leu Ala Lys Phe Pro Gly 660

25

⟨210⟩ 3

⟨211⟩ 23

<212> DNA

30 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

35

<400> 3

	. 4		23
	ctgaaa	agatc teggetatgg agg	۷۵
	<210>	4	
5	⟨211⟩	25	
	⟨212⟩	DNA	
	⟨213⟩	Artificial Sequence	
	⟨220⟩		
10	⟨223⟩	Description of Artificial Sequence:an artificially	
		synthesized primer sequence	
	<b>&lt;400&gt;</b>	4	
	aagaa	gctga gacgtcgatc cggct	25
15			
	⟨210⟩	5	
	⟨211⟩	21	
	⟨212⟩	DNA	
20	⟨213⟩	Artificial Sequence	
	⟨220⟩		
	⟨223⟩	Description of Artificial Sequence:an artificially	
0.5		synthesized primer sequence	
25	(400)		
	<400>		0.1
	aagcg	catct ccagccacat c	21
30	<210>	6	
50	<211>		
	⟨212⟩		
		Artificial Sequence	
		•	
35	⟨220⟩		
	⟨223⟩	Description of Artificial Sequence:an artificially	

## synthesized primer sequence

	⟨400⟩ 6	
	aagacattgg gcgtgaaagg	20
5		
	<210≻ 7	
	<211≻ 53	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence:an artificially	
	synthesized primer sequence	
15		
	<400> 7	
	ggggacaagt ttgtacaaaa aagcaggctg tcacagcgtc aaagaaaagg aag	53
20		
20	<210> 8	
	<211> 49	
	<212> DNA	
	<213> Artificial Sequence	
25	⟨220⟩	
23	<pre>&lt;220&gt; &lt;223&gt; Description of Artificial Sequence:an artificially</pre>	
	synthesized primer sequence	
	⟨400⟩ 8	
30	ggggaccact ttgtacaaga aagctgggtc cttctatgat gctatgcgg	49
	<210> 9	
	<211> 20	
35	<212> DNA	
	<213> Artificial Sequence	

<220>

<223> Description of Artificial Sequence:an artificially
 synthesized primer sequence

5

⟨400⟩ 9

agtgacagga gcgacaagag

20

10 <210> 10

<211> 18

<212> DNA

<213> Artificial Sequence

15 〈220〉

<223> Description of Artificial Sequence:an artificially
synthesized primer sequence

<400> 10

20 cctggagagt ccggttca


# [Brief Description of the Drawings]

5


- [Fig. 1] A photograph showing a three-way crossbred pig used for fattening/production.
- [Fig. 2] A graph showing the ability of each Mx1 genotype to suppress viral propagation at an MOI of 1.
- [Fig. 3] A graph showing the ability of each Mx1 genotype to suppress viral propagation at an MOI of 10.
- [Fig. 4] A photograph that compares the Mx1 expression levels in the respective transformed cells of 3T3, 3T3-0, 3T3-3, and 3T3-11, based on the results obtained using RT-PCR.
- [Fig. 5] A figure showing an "11-bp deletion" region in the last exon of the swine Mx1 gene, and nucleotide sequences of a primer pair to be used for amplifying the region.
- [Fig. 6] A photograph showing the detection of an 11-base deletion in the last exon of the swine Mx1 gene using PCR amplification.

# [Document Name] Drawings


[Fig. 1]




[Fig. 2]




[Fig. 3]








[Fig. 5]



5 [Fig. 6]



A/A A/A A/A A/A A/C A/A A/C A/A C/C Marker

[Document Name] Abstract

[Abstract]

5

[Problems to Be Solved]

An objective of the invention is to provide methods for determining genetic resistance of pigs to diseases caused by RNA viruses.

[Means for Solving the Problems]

The inventors investigated the impact of an 11-bp deletion in the swine Mx1 gene on the ability to suppress propagation of influenza viruses belonging to the myxovirus family, and revealed that the deletion led to a complete loss of the ability to suppress viral propagation.

Through the detection of the 11-bp deletion, pigs can be examined for their resistance to influenza viruses.

[Selected Drawings] None